Phase 2 N=39 Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
Pain
Primary: Number of Responders — 1; 2; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Vitamin D Levels in Stage IV Colorectal Cancer Patients
Colorectal Cancer
Primary: To Achieve Target Vitamin D Level — 41 participants
Phase 2 N=39 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants
Phase 2 N=26 Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival (PFS) Time — 82 days
Phase 2 N=186 REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants
Phase 2 N=23 Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants
Phase 2 N=12 Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
Neoplasms · Constipation · Opioid-Related Disorders
Primary: Rescue-free Laxation After Administration of Subcutaneous Methylnaltrexone — 33 percentage of participants
Phase 2 N=488 Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Hepatitis C, Chronic
Primary: Part 1: Rapid Virological Response (RVR) — 73.3; 100.0 Percentage of participants
Phase 2 N=17 Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Phase 2 N=95 Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Leukemia · Myelodysplastic Syndrome · Non-Hodgkin's Lymphoma
Primary: Death From GVHD — 4 participants
Phase 2 N=97 Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
Lymphoma
Primary: Overall Objective Response — 45; 31; 6; 1 participants
Phase 2 N=92 Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=9 Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
HIV Infections
Primary: Number of Participants With Suspected Adverse Drug Reaction Leading to Treatment Termination — 0 participants